Characterization of Interactions Between Taspine Derivate TPD7 and EGF Receptor by Cell Membrane Chromatography with Zonal Elution and Frontal Analysis

Characterization of Interactions Between Taspine Derivate TPD7 and EGF Receptor by Cell Membrane Chromatography with Zonal Elution and Frontal Analysis
复制标题

通过带区洗脱和前沿分析的细胞膜色谱法表征 Taspine 衍生物 TPD7 和 EGF 受体之间的相互作用

DOI:
10.1007/s10337-016-3189-7
复制
发表时间:
2016-11
期刊:
影响因子:
1.7
通讯作者:
Wenjuan Luo
Wenjuan Luo
中科院分区:
化学4区
文献类型:
--
作者:
Yingzhuan Zhan;Jing Li;Weina Ma;Dongdong Zhang;Wenjuan Luo

文献摘要

参考文献

相似文献

本研究建立了表皮生长因子受体(EGFR)高表达细胞膜层析方法来研究配体与EGFR之间的相互作用。通过正面分析评估配体对 EGFR 的亲和力。使用阿法替尼作为标记物的竞争研究用于评估 EGFR 特定结合位点发生的相互作用。结果表明,TPD7、HMQ1611和阿法替尼可能在EGFR上的单个共同结合位点上存在直接竞争。根据正面分析模型,阿法替尼的解离平衡常数(KD)为 6.05 × 10−7M,TPD7 为 6.91 × 10−7M,HMQ1611 为 9.68 × 10−7M。在细胞中,HMQ1611和TPD7均能抑制HEK293/EGFR细胞的生长,并以剂量​​依赖性方式显着降低HEK293/EGFR细胞中EGFR的磷酸化。研究表明TPD7和HMQ1611可以像阿法替尼一样结合EGFR。 TPD7比HMQ1611表现出更高的抑制作用,而TPD7和HMQ1611在HEK293/EGFR细胞中具有相似的作用,因此表明TPD7可能是高EGFR表达癌症的新型阻断剂。
In this study, a high epidermal growth factor receptor (EGFR) expression cell membrane chromatography method was established to investigate the interactions between ligands and EGFR. The affinity of ligands for EGFR was evaluated by frontal analysis. Competition study using afatinib as the marker was used to evaluate the interactions that occurred at specific binding sites on EGFR. The results indicated that TPD7, HMQ1611 and afatinib may have direct competition at a single common binding site on EGFR. From the model of frontal analysis, the dissociation equilibrium constants (KD) were 6.05 × 10−7M for afatinib, 6.91 × 10−7M for TPD7, and 9.68 × 10−7M for HMQ1611. In cells, HMQ1611 and TPD7 could both inhibit the growth of HEK293/EGFR cells and significantly decrease EGFR phosphorylation in HEK293/EGFR cells in a dose-dependent manner. The studies showed that TPD7 and HMQ1611 could bind EGFR as afatinib. TPD7 exhibited higher inhibitory effect than HMQ1611 while TPD7 and HMQ1611 had a similar effect in HEK293/EGFR cells, thus indicating that TPD7 might be the novel blocker for cancer with high-EGFR expression.
新型 VEGFR-2 抑制剂联苯脲衍生物的设计、合成和生物学评价
DOI: 10.1039/c3md00192j
发表时间: 2013-10
期刊: Medicine Chemical Communications
影响因子: --
作者:
Wang Cheng;Dong Jinyun;Zhang Yanmin;Wang Fang;Gao Hongping;Li Pengfei;Wang Sicen;Zhang Jie
通讯作者: Zhang Jie
高EGFR表达细胞系的构建及其与A431细胞生物学特性的比较
DOI: 10.5897/ajb10.143
发表时间: 2010-07
影响因子: --
作者:
Zhang, Yanmin;Xu, Xuemei;Luo, Wen-juan;Li, Xu
通讯作者: Li, Xu
DOI: 10.1007/bf02491836
发表时间: 2001-07-01
期刊: CHROMATOGRAPHIA
影响因子: 1.7
作者:
He, LC;Wang, SC;Geng, XD
通讯作者: Geng, XD
DOI: 10.1038/376337a0
发表时间: 1995-07-27
期刊: NATURE
影响因子: 64.8
作者:
MIETTINEN, PJ;BERGER, JE;DERYNCK, R
通讯作者: DERYNCK, R
DOI: 10.1124/mol.57.3.436
发表时间: 2000-03
影响因子: 3.6
作者:
R. Leppik;A. Mynett;S. Lazareno;N. Birdsall
通讯作者: R. Leppik;A. Mynett;S. Lazareno;N. Birdsall